Fiscal 2025 at a glance
In fiscal 2025 (the year to 28 December 2025), Johnson & Johnson reported revenue of $94.2B, up 6.0% from fiscal 2024, and net income of $26.8B (a net margin of 28.5%).
Diluted earnings per share were $11.03.
Operating activities generated $24.5B of cash; after $4.8B of capital expenditure, free cash flow was $19.7B.
From fiscal 2016 to fiscal 2025, revenue went from $71.9B to $94.2B, a compound annual growth rate of 3.0%.
Revenue and earnings
| Fiscal year | Revenue | Growth | Net income | Net margin |
|---|---|---|---|---|
| FY202528 Dec 2025 | $94.2B | +6.0% | $26.8B | 28.5% |
| FY202429 Dec 2024 | $88.8B | +4.3% | $14.1B | 15.8% |
| FY202331 Dec 2023 | $85.2B | +6.5% | $35.2B | 41.3% |
| FY20221 Jan 2023 | $80.0B | +1.6% | $17.9B | 22.4% |
| FY20212 Jan 2022 | $78.7B | −4.7% | $20.9B | 26.5% |
| FY20203 Jan 2021 | $82.6B | +0.6% | $14.7B | 17.8% |
| FY201929 Dec 2019 | $82.1B | +0.6% | $15.1B | 18.4% |
| FY201830 Dec 2018 | $81.6B | +6.7% | $15.3B | 18.8% |
| FY201731 Dec 2017 | $76.5B | +6.3% | $1.3B | 1.7% |
| FY20161 Jan 2017 | $71.9B | — | $16.5B | 23.0% |
Cash flow and balance sheet
| Fiscal year | Operating cash flow | Capital expenditure | Free cash flow | Cash | Total assets |
|---|---|---|---|---|---|
| FY202528 Dec 2025 | $24.5B | $4.8B | $19.7B | $19.7B | $199.2B |
| FY202429 Dec 2024 | $24.3B | $4.4B | $19.8B | $24.1B | $180.1B |
| FY202331 Dec 2023 | $22.8B | $4.5B | $18.2B | $21.9B | $167.6B |
| FY20221 Jan 2023 | $21.2B | $4.0B | $17.2B | $12.9B | $187.4B |
| FY20212 Jan 2022 | $23.4B | $3.7B | $19.8B | $14.5B | $182.0B |
| FY20203 Jan 2021 | $23.5B | $3.3B | $20.2B | $14.0B | $174.9B |
| FY201929 Dec 2019 | $23.4B | $3.5B | $19.9B | $17.3B | $157.7B |
| FY201830 Dec 2018 | $22.2B | $3.7B | $18.5B | $18.1B | $153.0B |
| FY201731 Dec 2017 | $21.1B | $3.3B | $17.8B | $17.8B | $157.3B |
| FY20161 Jan 2017 | $18.8B | $3.2B | $15.5B | $19.0B | $141.2B |
How these figures are built
- Figures as reported in Johnson & Johnson’s annual reports (Form 10-K), in US dollars, read from the SEC’s XBRL data. When a later report restates a year, the latest filed figure is shown.
- Free cash flow = operating cash flow − capital expenditure (purchases of property and equipment), computed by InvestIQ. Net margin = net income ÷ revenue. Compound annual growth rate: between the first and the last year of the table.
- Earnings per share are given for the latest fiscal year only: the SEC keeps each year as first filed, before any later stock split.
- Data extracted on 7 November 2026, updated after each annual report.
XBRL tags used
- Revenue
- us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Net income
- us-gaap:NetIncomeLoss
- Operating cash flow
- us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure
- us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Diluted earnings per share
- us-gaap:EarningsPerShareDiluted
- Total assets
- us-gaap:Assets
- Cash and equivalents
- us-gaap:CashAndCashEquivalentsAtCarryingValue
Latest filings
Questions
What was Johnson & Johnson’s revenue in fiscal 2025?
$94.2B for the fiscal year that ended on 28 December 2025, as reported in its 10-K annual report filed with the SEC (+6.0% year on year).
Is Johnson & Johnson profitable?
In fiscal 2025, Johnson & Johnson reported net income of $26.8B, a net margin of 28.5%. It reported a net profit in 10 of the last 10 fiscal years.
How much free cash flow does Johnson & Johnson generate?
$19.7B in fiscal 2025, against $19.8B in fiscal 2024: operating cash flow ($24.5B) minus capital expenditure ($4.8B), two reported figures that InvestIQ subtracts.
When does Johnson & Johnson’s fiscal year end?
Johnson & Johnson’s fiscal year ends in December. The latest reported fiscal year ended on 28 December 2025.
Where do these figures come from?
From Johnson & Johnson’s 10-K annual reports, through the SEC’s XBRL data (CIK 0000200406). They are the reported figures, in US dollars, not adjusted. This page gives no price, valuation, score or opinion.
Other companies
Reported figures, for information only. No price, valuation, score or opinion. Not investment advice.